Abstract
The current regime of intellectual property rights exercises monopoly control over the production and reproduction of knowledge. It attempts to throttle by economically restraining the products used to treat wide range of diseases, which are made unaffordable for the marginalised populations who do not have the purchasing power. The right of every human being to access the highest attainable standards of health is now fully recognised by numerous national constitutions and legally binding international human right treaties. The flexibilities contained in the trade-related aspects of intellectual property rights agreement and reaffirmed by the Doha Declaration provide important opportunities for World Trade Organization members to reduce prices and expand access to essential medicines. This article aims to throw light on the different strategies involved in overcoming patent-related challenges in the generic industries. It is the inbuilt responsibility of the Government to ensure necessary steps are being taken to access low priced or free medicines to marginalised populations.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of Research in Medical Education & Ethics
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
